drugset
drugset / Trial / NCT07118319

The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

NCT07118319 ↗

Phase 1 Recruiting 12 enrolled XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis

Timeline

Start
2025-09-15
Primary completion
2027-01-31
Completion
2028-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject XS228CN Cell therapy 5e+07 cells Intrathecal
Subject XS228CN Cell therapy 1e+08 cells Intrathecal

Indications

amyotrophic lateral sclerosis